|
Synonyms: ABBV-CLS-484 | AC484
Compound class:
Synthetic organic
Comment: ABBV-CLS-484 is an orally bioavailable, active-site inhibitor of the protein tyrosine phosphatases PTPN1/N2 that was developed by AbbVie, Calico Life Sciences, and the Broad Institute of MIT and Harvard. Its chemical structure was first disclosed at the AACR spring meeting in 2022, and subsequently published in a Nature Communications article in mid-2023 [2]. ABBV-CLS-484-mediated inhibition of PTPN1/N2 in T cells promotes a potent immune-dependent anti-tumour effect[1].
The structure of ABBV-CLS-484 is a match for the INN osunprotafib (INN PL129 August 2023). |
|
|||||||||||||||||||||||||||||||||||
| No information available. |
Summary of Clinical Use ![]() |
| ABBV-CLS-484 was progressed as a clinical candidate, for its potential to treat advanced solid tumours. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT04777994 | A Phase 1 Study With ABBV-CLS-484 in Subjects With Locally Advanced or Metastatic Tumors | Phase 1 Interventional | Calico Life Sciences LLC | ||